• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
American CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell Therapy
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
    • LONG COVID CLINICAL TRIAL
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

American CryoStem to Unveil ATGRAFT Adipose Tissue Storage Service at the American Academy of Cosmetic Surgery Annual Conference

January 15, 2013

EATONTOWN, N.J., Jan. 15, 2013 (GLOBE NEWSWIRE) — American CryoStem Corporation (OTCQB:CRYO), a leading biotech company in the regenerative medicine industry, announced today it will participate at the American Academy of Cosmetic Surgery (AACS) annual conference January 16-19, 2013 in Las Vegas (booth #339) to showcase the newly launched ATGRAFT™, adipose tissue storage service.

American CryoStem Medical Advisory Board Member, Mel Bircoll MD, who pioneered liposuction and was the first to incorporate fat transfer into his practice in the 1980’s will be presenting to the AACS members, Wednesday, January 16, 2013. In his Continuing Medical Education (CME) presentation, “My 33 Year Experience with Fat Transfer – with a Look to the Future” he will discuss the latest technologies and trends for adipose tissue (fat) storage and transfers. Additionally, during the general session, Saturday, January 19, 2013, Dr. Bircoll’s topic of discussion will be, “Innovations for Fat Transfer – Past, Present and Future.”

The AACS 29th Annual Scientific Meeting is a multi-specialty, international meeting for cosmetic surgeons and health care professionals. John S. Arnone, CEO commented, “We are participating this year at the conference to unveil our ATGRAFT™ tissue storage service and to speak directly with physicians who use our services.” Mr. Arnone further commented, “ATGRAFT™ is a clinical solution for physicians to provide their patients the highest quality fat transfer procedures and technologies. Using the patient’s stored tissue allows for bio-compatible layered augmentation and corrective procedures, eliminates multiple liposuctions, provides maximum flexibility, and produces natural lasting results.”

Physicians that would like to offer ATGRAFT™ tissue storage services to their patients should visit us at booth #339 at the AACS conference, call 732-747-1007 or email info@americancryostem.com for an information kit.

About American CryoStem: American CryoStem Corporation (OTCQB:CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and regenerative medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.

Investor Relations Contact:
American CryoStem Corporation
732-747-1007

www.americancryostem.com

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners